References
- Tam C S, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975–980
- Hallek M, Fingerle-Rowson G, Fink A-M, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood (Suppl) 2008; 112: 325, (Abstract)
- O'Brien S, Wierda W G, Faderl S, et al. FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL). Blood (Suppl) 2005; 106: 2117, (Abstract)
- Faderl S, Wierda W, O'Brien S, et al. A phase II study of fludarabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R) (FCM-R) in previously untreated patients (pts) with CLL <=70 years (yrs). J Clin Oncol (Meeting Abstracts) 2006; 24: 6607
- Wierda W, O'Brien S, Faderl S, et al. CFAR, an active frontline regimen for high-risk patients with CLL, including those with Del 17p. Blood (Suppl) 2008; 112: 2095, (Abstract)
- Montillo M, Cafro A M, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002; 87: 695–700
- O'Brien S M, Kantarjian H M, Thomas D A, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98: 2657–2663
- Wendtner C M, Ritgen M, Schweighofer C D, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093–1101
- Byrd J C, Peterson B L, Rai K R, et al. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma 2009; 50: 1589–1596
- O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008; 111: 1816–1819
- Ferrajoli A, Lee B N, Schlette E J, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291–5297